These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 9849695

  • 1. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience.
    Micallef IN, Chhanabhai M, Gascoyne RD, Shepherd JD, Fung HC, Nantel SH, Toze CL, Klingemann HG, Sutherland HJ, Hogge DE, Nevill TJ, Le A, Barnett MJ.
    Bone Marrow Transplant; 1998 Nov; 22(10):981-7. PubMed ID: 9849695
    [Abstract] [Full Text] [Related]

  • 2. Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation.
    Lynch BA, Vasef MA, Comito M, Gilman AL, Lee N, Ritchie J, Rumelhart S, Holida M, Goldman F.
    Bone Marrow Transplant; 2003 Sep; 32(5):527-33. PubMed ID: 12942101
    [Abstract] [Full Text] [Related]

  • 3. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W, Blazar B.
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE.
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation.
    Chiang KY, Hazlett LJ, Godder KT, Abhyankar SH, Christiansen NP, van Rhee F, Lee CG, Bridges K, Parrish RS, Henslee-Downey PJ.
    Bone Marrow Transplant; 2001 Dec; 28(12):1117-23. PubMed ID: 11803352
    [Abstract] [Full Text] [Related]

  • 8. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D, Chan KW, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C, Khouri I, Huh YO, Vreisendorp H, Deisseroth AB.
    Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
    [Abstract] [Full Text] [Related]

  • 9. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute.
    Hou HA, Yao M, Tang JL, Chen YK, Ko BS, Huang SY, Tien HF, Chang HH, Lu MY, Lin TT, Lin KH, Hsiao CH, Lin CW, Chen YC.
    Bone Marrow Transplant; 2009 Feb; 43(4):315-21. PubMed ID: 18836488
    [Abstract] [Full Text] [Related]

  • 10. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia.
    Buyck HC, Ball S, Junagade P, Marsh J, Chakrabarti S.
    Bone Marrow Transplant; 2009 May; 43(10):813-6. PubMed ID: 19104495
    [Abstract] [Full Text] [Related]

  • 11. [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
    Xu LP, Huang XJ, Liu DH, Chen YH, Shi HX, Chen DB.
    Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):996-9. PubMed ID: 18478915
    [Abstract] [Full Text] [Related]

  • 12. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
    Zakerinia M, Khojasteh HN, Ramzi M, Haghshenas M.
    Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
    [Abstract] [Full Text] [Related]

  • 13. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H, Kitaori K, Kasai M, Shimokawa T, Kato C, Yamanishi H, Ueda R, Morishima Y.
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [Abstract] [Full Text] [Related]

  • 14. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 15. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M, Badwal S, Pandey R, Srivastava A, Sharma RK, Gupta RK.
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [Abstract] [Full Text] [Related]

  • 16. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
    Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski WR, Hanson G, Horowitz M, Lawton C, Margolis J, Peitryga D, Vesole D.
    Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781
    [Abstract] [Full Text] [Related]

  • 17. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M.
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [Abstract] [Full Text] [Related]

  • 18. T cell lymphoproliferative disorder following bone marrow transplantation for severe aplastic anemia.
    Wang LC, Lu MY, Yu J, Jou ST, Chiang IP, Lin KH, Lin DT.
    Bone Marrow Transplant; 2000 Oct; 26(8):893-7. PubMed ID: 11081391
    [Abstract] [Full Text] [Related]

  • 19. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
    Byrne JL, Stainer C, Cull G, Haynes AP, Bessell EM, Hale G, Waldmann H, Russell NH.
    Bone Marrow Transplant; 2000 Feb; 25(4):411-7. PubMed ID: 10723585
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of histogenesis of B-lymphocytes in pediatric EBV-related post-transplant lymphoproliferative disorders.
    Abed N, Casper JT, Camitta BM, Margolis D, Trost B, Orentas R, Chang CC.
    Bone Marrow Transplant; 2004 Feb; 33(3):321-7. PubMed ID: 14688820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.